Shyam Masrani

Company: Medicxi

Job title: Principal

Seminars:

Securing Buy-In from Pharma Partnerships and Investors 2:30 pm

How can we effectively present proof of concept, pharmacokinetic (PK), and toxicity data to persuade conservative investors to fund next-generation conjugate projects in Europe? Which specific metrics and evidence, such as efficacy data, market potential, or comparative advantages over existing therapies, are most persuasive for investors when considering funding for next-generation conjugates? In what ways…Read more

day: Conference Day 2